Atea Pharmaceuticals (AVIR) Common Equity (2019 - 2026)

Atea Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $233.7 million for Q1 2026.

• On a quarterly basis, Common Equity fell 43.15% year-over-year to $233.7 million in Q1 2026; TTM through Mar 2026 was $233.7 million, a 43.15% decrease from a year earlier, with the FY2025 full-year figure at $275.4 million, down 37.24% from the prior year.
• Common Equity slipped to $233.7 million in Q1 2026 per AVIR's latest filing, from $275.4 million in the prior quarter.
• Across five years, Common Equity topped out at $679.9 million in Q1 2022 and bottomed at $233.7 million in Q1 2026.
• The 5-year median for Common Equity is $504.4 million (2024), against an average of $498.8 million.
• Across the five-year window, Common Equity climbed 15.97% in 2022 and sank 43.15% in 2026, its largest moves.
• Year by year, Common Equity stood at $640.6 million in 2022, then slipped by 13.33% to $555.2 million in 2023, then fell by 20.95% to $438.9 million in 2024, then plunged by 37.24% to $275.4 million in 2025, then decreased by 15.15% to $233.7 million in 2026.
• Per Business Quant, the three latest AVIR Common Equity figures stand at $233.7 million (Q1 2026), $275.4 million (Q4 2025), and $315.8 million (Q3 2025).